Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic

Executive Summary

EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.

Related Content

Decision Time At CHMP: Portola and Aegerion In Spotlight
Bumper Number Of 'Oral Explanations' Due At CHMP Meeting
New EU Submissions For Pfizer’s Lorlatinib, Teva’s Fremanezumab - And A CV Filing For Canakinumab
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Lilly, Novartis, Jazz and Ionis Take New Products To EMA
Keeping Track: A Second Straight Burst Of FDA Approvals
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts